Nanoviricides, Inc. (NNVC) — SEC Filings
Nanoviricides, Inc. (NNVC) — 17 SEC filings. Latest: 8-K (Nov 26, 2025). Includes 7 8-K, 6 10-Q, 2 DEF 14A.
View Nanoviricides, Inc. on SEC EDGAR
Overview
Nanoviricides, Inc. (NNVC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: NanoViricides, Inc. (NNVC) reported a net loss of $1,785,058 for the three months ended September 30, 2025, a significant improvement from the $3,126,811 net loss in the same period of 2024. This 42.9% reduction in net loss was primarily driven by a substantial decrease in operating expenses, which
Sentiment Summary
Across 17 filings, the sentiment breakdown is: 15 neutral, 2 mixed. The dominant filing sentiment for Nanoviricides, Inc. is neutral.
Filing Type Overview
Nanoviricides, Inc. (NNVC) has filed 7 8-K, 6 10-Q, 2 DEF 14A, 2 10-K with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (17)
Risk Profile
Risk Assessment: Of NNVC's 15 recent filings, 3 were flagged as high-risk, 10 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $ -1,785,058 |
| EPS | $ -0.10 |
| Debt-to-Equity | 0.16 |
| Cash Position | $ 1,125,711 |
| Operating Margin | -100.0% |
| Total Assets | $ 8,357,080 |
| Total Debt | $ 1,182,386 |
Key Executives
- Anil Diwan
- Peter Campitiello
- Meeta Vyas
- Peter Campitiello, Esq.
Industry Context
NanoViricides, Inc. operates in the highly competitive and capital-intensive biotechnology sector, focusing on antiviral drug development. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on clinical trial outcomes and the ability to secure substantial funding for research, development, and eventual commercialization.
Top Tags
10-Q (5) · financials (4) · Biotechnology (3) · corporate-governance (3) · Antiviral Drugs (2) · Nanomedicine (2) · filing (2) · biotech (2) · shareholder-vote (2) · SEC Filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $1,785,058 | for the three months ended September 30, 2025, a 42.9% reduction from prior year |
| Cash and Cash Equivalents | $1,125,711 | as of September 30, 2025, down from $1,558,564 at June 30, 2025 |
| Accumulated Deficit | $150,626,919 | as of September 30, 2025, indicating significant historical losses |
| Research and Development Expenses | $993,066 | for the three months ended September 30, 2025, a 48.7% decrease year-over-year |
| General and Administrative Expenses | $803,619 | for the three months ended September 30, 2025, a 34.9% decrease year-over-year |
| Additional Capital Raised | $6,000,000 | between October 1, 2025, and November 12, 2025 |
| Common Shares Outstanding | 17,556,079 | as of September 30, 2025, up from 16,606,832 at June 30, 2025, indicating dilution |
| Net Loss Per Common Share | $0.10 | for the three months ended September 30, 2025, improved from $0.23 in prior year |
| Annual Meeting Date | 2025-11-08 | Date of the Annual Meeting of Stockholders |
| Annual Meeting Time | 10:00 a.m. | Eastern Daylight Time for the Annual Meeting |
| Record Date | 2025-10-03 | Date for determining stockholders entitled to vote |
| Common Stock Shares Outstanding | 17,431,000 | Shares entitled to one vote each as of October 3, 2025 |
| Series A Preferred Stock Shares Outstanding | 905,717 | Shares entitled to nine votes each as of October 3, 2025 |
| Series A Preferred Stock Votes | 8,151,453 | Total votes from Series A Preferred Stock |
| Aggregate Total Votes | 25,582,453 | Total voting power across all stock classes |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Nanoviricides, Inc. (NNVC)?
Nanoviricides, Inc. has 17 recent SEC filings from Jan 2024 to Nov 2025, including 7 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NNVC filings?
Across 17 filings, the sentiment breakdown is: 15 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Nanoviricides, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Nanoviricides, Inc. (NNVC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Nanoviricides, Inc.?
Key financial highlights from Nanoviricides, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NNVC?
The investment thesis for NNVC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Nanoviricides, Inc.?
Key executives identified across Nanoviricides, Inc.'s filings include Anil Diwan, Peter Campitiello, Meeta Vyas, Peter Campitiello, Esq..
What are the main risk factors for Nanoviricides, Inc. stock?
Of NNVC's 15 assessed filings, 3 were flagged high-risk, 10 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Nanoviricides, Inc.?
Forward guidance and predictions for Nanoviricides, Inc. are extracted from SEC filings as they are enriched.